From: Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis
Study | Year | Comparator | Design | Participants | Interventions (with levels) | Definition of relapse/recurrence | Quality (rating) | Previous lithium/comparator use | Lithium/comparator serum level achieved |
---|---|---|---|---|---|---|---|---|---|
Prien [1973] | 1973 | Placebo | Random assignment, 2-year follow-up | Patients with manic depressive disorder, manic type (n = 205), age 17 to 60 years; most recent episode: manic | Lithium (0.5 to 1.4 mEq/l); placebo | Emergent manic or depressive attack measured on Global Affective Scale requiring hospitalization (severe relapse) or supplementary medication (moderate relapse); combined moderate and severe relapse rates used | Allocation concealment unclear (B); participants and clinical raters blinded to treatment allocation; treating physician not blinded (A) | Following remission of the acute manic episode and prior to discharge (time of randomization) patients were stabilized on lithium (0.5 to 1.4 mEq/l) | Median serum lithium level 0.7 mEq/l |
Kane [1982] | 1982 | Placebo | Random assignment, up to 2-year follow-up | Patients with bipolar II disorder (Research Diagnostic Criteria) (n = 22), age 18 to 65 years; patients had been euthymic for 6 months prior to entry into the study | Lithium (0.8 to 1.2 mEq/l); imipramine (100 to 150 mg per day); lithium plus imipramine; placebo | Emergent mood episode meeting Research Diagnostic Criteria for major depressive disorder for 1 week, minor depressive disorder for 4 weeks, manic episode for any duration, or hypomanic episode for 1 week | Allocation concealment unclear (B); patients and physicians blinded to treatment allocation (A) | Patients had been on open uncontrolled continuation treatment for 6 months (except for the last 6 weeks (open treatment with imipramine)) before they were randomly assigned to treatment condition | Not available |
Greil [1997] | 1997 | Carbamazepine | Random assignment, 2.5 years observation period, primary aim was to assess efficacy of carbamazepine | Patients with current episode of bipolar affective disorder (ICD-9: 296.2, 296.3, 296.4) (n = 144), no preventive treatment immediately before current episode, age 18 to 65 years | Lithium (0.6 to 0.8 mmol/l); carbamazepine (4 to 12 μg/ml) | Recurrence, i.e. rating of psychopathology of 5 (=recurrence) or 6 (=extremely severe recurrence) corresponding to the recurrence of an affective episode in line with the Research Diagnostic Criteria | Non-blind design, randomization procedure by Efron (1971) (A); Allocation concealment adequate (A): central allocation through coordinating study centre, treatment group allocation by phone at the moment of randomization | Stabilization phase: psychotropic medication according to the free decision of the treating physician was gradually reduced and, if possible, discontinued before randomization; 84% never had received prophylactic treatment before | 0.63 ± 0.12 mmol/l |
Bowden [2000] | 2000 | Placebo, valproate | Random assignment, 1-year follow-up, primary aim was to assess efficacy of divalproex | Patients with bipolar I disorder (DSM-III-R) with index manic episode according to Structured Clinical Interview for DSM-III-R (n=372), those with high suicide risk excluded, age 18-75 years | Lithium (0.8 to 1.2 mEq/l); divalproex (71 to 125 ug/ml); placebo | Emergent manic episode (Mania Rating Scale score of 16 or more or requiring hospitalization) or depressive episode (requiring antidepressant use or premature study withdrawal) | Allocation concealment unclear (B); patients, clinicians, and outcome assessors blinded to treatment allocation (A) | Before randomization, 117/372 were treated with open-label divalproex, 124 with lithium, 50 with both drugs, 81 with neither drug; lithium as well as divalproex were gradually reduced and withdrawn during the first 2 weeks of maintenance treatment | Mean (SD) serum lithium concentration by day 30: 1.0 ± 0.48 mEq/l; mean (SD) valproate concentration by day 30: 84.8 ± 29.9 ug/ml |
Bowden [2003] | 2003 | Placebo, lamotrigine | Random assignment, 1-year follow-up, primary aim was to assess efficacy of lamotrigine | Patients with bipolar I disorder recently recovered from a manic or hypomanic episode (DSM-IV) (n = 175), age ≥18 years | Lithium (0.8 to 1.1 mEq/l); placebo; lamotrigine (100 to 400 mg per day) | Intervention (additional medication or ECT) required for any mood episode; secondary outcomes subdivided by type of mood episode (manic/hypomanic/mixed or depressive) | Allocation concealment unclear (B); patients, clinicians, and outcome assessors blinded to treatment allocation (A) | Majority of participants had a prior history of lithium use (31/46: 70% in lithium group; 42/69: 67% in placebo group; 38/58: 72% in lamotrigine group). 18% of participants during the initial part of the 8- to 16-week open-label phase received lithium, the dosage of which was tapered over at least 3 weeks and discontinued a minimum of 1 week before they entered the double-blind phase of the study. All participants received open-label lamotrigine during the open-label phase (target dosage 200 mg/d; minimum 100 mg/d). Concomitant psychotropic medications were permitted during the open-label phase as needed to treat an ongoing manic or hypomanic episode but were discontinued a minimum of 1 to 2 weeks before entry into the double-blind phase. | Not available |
Calabrese [2003] | 2003 | Placebo, lamotrigine | Random assignment, 1-year follow-up, primary aim was to assess efficacy of lamotrigine | Patients with bipolar I disorder recently recovered from a major depressive episode according to DSM-IV (n = 463), age ≥18 years | Lithium (0.8 to 1.1 mEq/l); placebo; lamotrigine (50 to 400 mg per day) | Intervention (additional medication or ECT) required for any mood episode; secondary outcomes subdivided by type of mood episode (manic/hypomanic/mixed or depressive) | Allocation concealment unclear (B); patients, clinicians, and outcome assessors blinded to treatment allocation (A) | Majority of participants had a prior history of lithium use (57% to 62% of patients had received prior lithium treatment at some point, with 67% to 72% of these patients having achieved good clinical response and 80% to 85% having tolerated such prior treatment). 20% of participants in open label run in received lithium, dosage tapered over at least 3 weeks and discontinued a minimum of 1 week prior to entering the double-blind phase; any psychotropic medication permitted during 8- to 16- week open-label phase; all patients received lamotrigine (target dosage 200 mg/d; minimum 100 mg/d) as adjunctive therapy or monotherapy; all psychotropic medication other than lamotrigine were discontinued at least 7 days prior to randomization | Steady-state mean ± SD serum levels of 0.8 ± 0.3 mEq/l |
Hartong [2003] | 2003 | Carbamazepine | Random assignment, 2-year study | Patients with bipolar disorder (DSM-III-R) with at least two episodes during the last 3 years, recovered from last episode (n = 94), age ≥18 years | Lithium (0.6 to 1.0 mmol/l); carbamazepine (6 to 10 mg/l)) | Recurrence of an episode of (hypo)mania or major depression according to DSM-III-R criteria | Allocation concealment adequate: pharmacy-controlled block randomization (A); double dummy design, double blind (A) | Total lithium/carbamazepine treatment during lifetime ≤6 months; at randomization, no patient received antidepressants, antipsychotics, or benzodiazepines. | Lithium level mean (SD): 0.75 (0.18) mmol/l; carbamazepine level mean (SD): 6.8 (1.2) mg/l |
Geddes [2010] | 2010 | Valproate | Random assignment, 24-month follow-up, primary aim was to assess efficacy of lithium-valproate combination therapy | Patients with bipolar I disorder on the basis of a previous episode of mania meeting DSM-IV criteria (n = 330), age ≥16 years; most recent episodes 52% mania, 34% depression, 12% mixed, 3% cycling | Lithium (0.4 to 1.0 mmol/l); valproate (750 to 1,250 mg) | Initiation of new intervention for an emergent mood episode, including drug treatment or admission to hospital | Randomization computerized, minimization; allocation concealment adequate: central allocation via telephone (A); investigators and participants informed of treatment allocation, trial management team masked to treatment assignment (A) | Before randomization active run-in of 4 to 8 weeks: all patients received lithium and valproate (lithium serum level 0.4 to 1.0 mmol/l; valproate dose at least 750 mg or valproic acid serum concentration at least 50 μg/ml) | Not available |
Licht [2010] | 2010 | Lamotrigine | Random assignment, up to 5.8-year follow-up, primary aim was to assess efficacy of lamotrigine | Patients with bipolar I disorder according to DSM-IV with at least two episodes within the last 5 years (n = 155) recruited during or in the aftermath of an index episode, age ≥18 years; index episode either depression (51%), mania (41%), or mixed mania (8%) according to the Cincinnati criteria, onset within the last year prior to randomization | Lithium (0.5 to 1.0 mmol/l); lamotrigine (up-titrated to 400 mg/day) | Psychotropic treatment (in addition to study drug and benzodiazepines) and/or hospitalization still required at month 6 after randomization; psychotropic treatment (in addition to study drug and benzodiazepines) during at least 1 week and/or hospitalization during at least 1 week still required after month 6 (after randomization) | Allocation concealment adequate: central allocation; computer-generated randomization plan, block randomization (A) | Prior lithium prophylaxis: 13 (17%) in lamotrigine group, 15 (19%) in lithium group; patients receiving lithium until randomization and assigned to lamotrigine group: lithium was tapered off over 1 to 3 months; patients receiving lamotrigine until randomization and assigned to lithium group: discontinuation of lamotrigine at randomization. Additional antipsychotic or antidepressant drugs were allowed in the first 6 months after randomization, investigators were encouraged to achieve monotherapy at month 6. Benzodiazepines allowed throughout the study. | Serum lithium level: mean 0.69 mmol/l (SD = 0.20); lamotrigine dose: mean 379 mg (SD = 66) (serum level 22.5 (12.7) μmol/l) |
Amsterdam [2010] | 2010 | Placebo, fluoxetine | Random assignment, up to 1-year follow-up | Patients with bipolar II disorder (n = 81) recently recovered from depressive episode with fluoxetine treatment, age 19 to 67 years | Lithium (0.5 to 1.5 mEq/l); fluoxetine (10 to 40 mg per day); placebo | Depressive relapse defined as HAMD score of 14 or more and meeting diagnostic criteria for major depressive episode. Hypomanic episode defined by DSM-IV criteria | Allocation concealment unclear (B); patients, clinicians, and outcome assessors blinded to treatment allocation (A) | Initial fluoxetine monotherapy was administered on the basis of response and tolerability. Patients who had a final HAM-D score ≤ 8 by week 12 of treatment were randomly assigned to different treatment arms. Patients assigned to fluoxetine group who previously took >40 mg/day of fluoxetine: dosage reduced to 40 mg/day; previously ≤ 40 mg/day: dosage maintained; patients assigned to lithium group: fluoxetine therapy discontinued. Lithium therapy initiated at 600 mg/day for 1 week, increased to 900 mg/day in week 2, continued until serum level of 0.5 to 1.5 mEq/l achieved by week 4. | Mean average serum lithium level was 0.69 mmol/liter (SD = 0.27), mean average maximum fluoxetine dose 34.3 mg/day (SD = 7.9) |
Weisler et al. [2011] | 2011 | Placebo, quetiapine | Random assignment, up to 2-year follow-up | Patients with bipolar I disorder (DSM-IV) recently recovered from a manic (53.6%), depressive (28%) or mixed episode (18.4%) (n = 1,172), age ≥18 years | Lithium (0.6 to 1.2 mEq/l); quetiapine (300 to 800 mg per day); placebo | Emergent mood event requiring medication or hospitalization, YMRS or MADRS 20 or more on two consecutive assessments, discontinuation attributed to mood event by investigator | Allocation by centralized randomization and drug allocation system (A); patients, clinicians, and outcome assessors blinded to treatment allocation (A) | All patients received open-label quetiapine (300 - 800 mg/d) for 4-24 weeks. Patients achieving stabilization on quetiapine were randomized to different treatment arms. Replacement of quetiapine tablets used during prerandomization phase started on day 1 and was completed by 2 weeks. Known intolerance or lack of response to lithium was an exclusion criterion | Mean (SD) median serum concentration was 0.63 (0.45) mEq/l; mean (SD) median quetiapine dose 546 (173) mg |